Attached files

file filename
EX-10.50 - EX-10.50 - ARENA PHARMACEUTICALS INCarna-ex1050_631.htm
10-K - 10-K - ARENA PHARMACEUTICALS INCarna-10k_20201231.htm
EX-32.1 - EX-32.1 - ARENA PHARMACEUTICALS INCarna-ex321_10.htm
EX-31.2 - EX-31.2 - ARENA PHARMACEUTICALS INCarna-ex312_9.htm
EX-31.1 - EX-31.1 - ARENA PHARMACEUTICALS INCarna-ex311_8.htm
EX-21.1 - EX-21.1 - ARENA PHARMACEUTICALS INCarna-ex211_7.htm
EX-10.45 - EX-10.45 - ARENA PHARMACEUTICALS INCarna-ex1045_632.htm
EX-10.22 - EX-10.22 - ARENA PHARMACEUTICALS INCarna-ex1022_633.htm
EX-10.12 - EX-10.12 - ARENA PHARMACEUTICALS INCarna-ex1012_634.htm
EX-10.11 - EX-10.11 - ARENA PHARMACEUTICALS INCarna-ex1011_635.htm
EX-10.2 - EX-10.2 - ARENA PHARMACEUTICALS INCarna-ex102_636.htm
EX-10.1 - EX-10.1 - ARENA PHARMACEUTICALS INCarna-ex101_630.htm

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

The Board of Directors

Arena Pharmaceuticals, Inc.:

We consent to the incorporation by reference in the registration statements (Nos. 333-160329, 333-182238, 333-189213, 333-204999, 333-212012, 333-214529, 333-217805, 333-218905, 333-225608, 333-232142, and 333-239330) on Form S-8 and (Nos. 333-112542, 333-136023, 333-160983, 333-167498, and 333-219237) on Form S-3 of Arena Pharmaceuticals, Inc. of our reports dated February 23, 2021, with respect to the consolidated balance sheets of Arena Pharmaceuticals, Inc. as of December 31, 2020 and 2019, the related consolidated statements of operations and comprehensive (loss) income, equity, and cash flows for each of the years in the three-year period ended December 31, 2020, and the related notes, and the effectiveness of internal control over financial reporting as of December 31, 2020, which reports appear in the December 31, 2020 annual report on Form 10-K of Arena Pharmaceuticals, Inc. Our report refers to the adoption of Accounting Standards Codification Topic 842, Leases.

/s/ KPMG LLP

San Diego, California

February 23, 2021